Frontpage Hero

Because we care, we need to act

Sobi Annual General Meeting

Annual General Meeting 2019

The Annual General Meeting (“AGM”) in Swedish Orphan Biovitrum AB (publ) will be held on Thursday, May 9 at 3.00 p.m. at Grand Hôtel, S. Blasieholmshamnen 8, Stockholm, Sweden.
Annual and Sustainability Report

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter

Press releases

Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards. The companies were nominated in the category of Industry Innovation in recognition of the US Food and Drug Administration...

03/25/2019 - 08:30

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) at the 2019 Transplantation and Cellular...

02/26/2019 - 09:00

Save the date for Swedish Orphan Biovitrum AB (publ) (Sobi™) Capital Markets Day on 14 May 2019. The event will take place at Karolinska Institutet Biomedicum, Solnavägen 9, Solna, from 12:30 – 16:30. A lighter lunch will be served at 11:30. We also welcome all...

02/21/2019 - 13:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the fourth quarter and full-year 2018. Total revenues grew 37 per cent compared with Q4 2017 (29 per cent at constant exchange rates (CER)) and amounted to SEK 2,571 M. EBITA was SEK 916 M, an...

02/20/2019 - 08:00
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden